Key result
Targeting cardiac metabolic pathways emerges as a promising therapeutic strategy for heart failure and ischemia.
Why the study?
The study aimed to summarize the main metabolic changes detectable in the heart under acute and chronic cardiac pathologies and analyze possible therapeutic targets.
Does pharmacological modulation of cardiac metabolic pathways improve outcomes in acute and chronic cardiac pathologies?
Does pharmacological modulation of cardiac metabolic pathways improve outcomes in acute and chronic cardiac pathologies?
Answers are grounded in this paper and cite their sources.
Metabolic reprogramming is a fundamental mechanism in the transition from a healthy to a diseased heart, offering new therapeutic avenues for treating heart failure and ischemic heart disease.
Cardiac metabolism represents a crucial and essential connecting bridge between the healthy and diseased heart. The cardiac muscle, which may be considered an omnivore organ with regard to the energy substrate utilization, under physiological conditions mainly draws energy by fatty acids oxidation. Within cardiomyocytes and their mitochondria, through well-concerted enzymatic reactions, substrates converge on the production of ATP, the basic chemical energy that cardiac muscle converts into mechanical energy, i.e., contraction. When a perturbation of homeostasis occurs, such as an ischemic event, the heart is forced to switch its fatty acid-based metabolism to the carbohydrate utilization as a protective mechanism that allows the maintenance of its key role within the whole organism. Consequently, the flexibility of the cardiac metabolic networks deeply influences the ability of the heart to respond, by adapting to pathophysiological changes. The aim of the present review is to summarize the main metabolic changes detectable in the heart under acute and chronic cardiac pathologies, analyzing possible therapeutic targets to be used. On this basis, cardiometabolism can be described as a crucial mechanism in keeping the physiological structure and function of the heart; furthermore, it can be considered a promising goal for future pharmacological agents able to appropriately modulate the rate-limiting steps of heart metabolic pathways.
No takes yet. Share an insight, caveat, or question.
Pasqua et al. (2021) conducted a review in Acute and chronic cardiac pathologies (e.g., myocardial infarction, heart failure, inherited cardiomyopathies). Pharmacological modulation of cardiac metabolic pathways was evaluated. Pharmacological modulation of cardiac metabolic pathways represents a promising therapeutic frontier for treating acute and chronic cardiac pathologies like heart failure and ischemia.
Synapse has enriched 10 related papers. Consider them for comparative context: